跳到主要导航 跳到搜索 跳到主要内容

Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells

  • Cong Long
  • , Wei Guo
  • , Heng Zhou
  • , Jingchao Wang
  • , Huan Wang
  • , Xiaoping Sun*
  • *此作品的通讯作者

科研成果: 期刊稿件 › 论文 › 同行评审

23 引用 (Scopus)

摘要

Kaposi's sarcoma-associated herpesvirus (KSHV) can establish a life-long persistence in the host after primary infection and is associated with certain malignancies, which are resistant to conventional chemotherapeutic agents with a poor prognosis. Latency-associated nuclear antigen 1 (LANA1) encoded by KSHV is essential for segregation, replication and maintenance of viral genome. In addition, LANA1 upregulates the transcriptional activity of signal transducer and activator of transcription 3 (STAT3), which plays an important role in promoting survival of KSHV-associated primary effusion lymphoma (PEL) cells. Furthermore, LANA1 mediates transcriptional modulation of KSHV and host genome in host cells. In the present study, the antitumor effect of triptolide was assessed. CCK-8 assays were performed to demonstrate that the proliferations of PEL cells were efficiently inhibited by triptolide in a dose-and time-dependent manner. Flow cytometric results indicated that triptolide induced cell cycle arrest and apoptosis. Western blot results suggested that triptolide downregulated LANA1 expression and reduced half-life of LANA1 in the KSHV-infected malignant cells. Viral titer experiments indicated that triptolide treatment impaired the number of viral DNA copies and the production of virions in BCBL-1 cells. Triptolide also suppressed STAT3 activity and inhibited secretion of IL-6 in PEL cells. In a mouse xenograft model of primary effusion lymphoma by BCBL-1 cells, triptolide treatment significantly inhibited ascites formation and diffused organ infiltration. These results indicate that triptolide impairs the expression of LANA1 and shows antitumor activity against PEL in vitro and in vivo. Triptolide may be a potential agent for treatment of PEL.
源语言英语
页(从-至)1519-1530
页数12
期刊International Journal of Oncology
卷48
期4
DOI
出版状态已出版 - 4月 2016

基金资助

The present study was supported by the Initiative Research Program of Wuhan University (no. 410100020), the Advanced Talent Independent Research Program of Wuhan University (no. 410500011), and the National Natural Science Foundation of China (no. 210700228).

关键词

  • triptolide
  • latency-associated nuclear antigen 1
  • viral titers
  • Kaposi's sarcoma-associated herpesvirus
  • primary effusion lymphoma

收录

  • Scopus
  • SCIE

学术指纹

探究 'Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells' 的科研主题。它们共同构成独一无二的学术指纹。

引用此